Spectral Medical Inc. (TSE:EDT – Get Free Report) reached a new 52-week low on Monday. The stock traded as low as C$0.98 and last traded at C$1.01, with a volume of 16,918 shares. The stock had previously closed at C$1.00.
Spectral Medical Trading Up 1.0%
The company has a debt-to-equity ratio of 26.03, a current ratio of 0.61 and a quick ratio of 0.45. The company has a market cap of C$296.49 million, a price-to-earnings ratio of -8.42 and a beta of 0.93. The business has a 50 day simple moving average of C$1.21 and a 200 day simple moving average of C$1.32.
About Spectral Medical
Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin¿ (‘PMX’). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s FDA cleared Endotoxin Activity Assay (EAA¿), the clinically available test for endotoxin in blood. PMX is approved for therapeutic use in Japan and Europe, licensed by Health Canada, and has been used safely and effectively with over 360,000 units sold worldwide to date.
Further Reading
- Five stocks we like better than Spectral Medical
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Spectral Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Medical and related companies with MarketBeat.com's FREE daily email newsletter.
